miRNA-based diagnostics | GenomeWeb

miRNA-based diagnostics

NEW YORK (GenomeWeb) – Cantor Fitzgerald today initiated coverage of miRNA-based diagnostics firm Rosetta Genomics with a Hold rating and a $4 price target on the company's stock.

NEW YORK (GenomeWeb) – PDI said after the close of the market Wednesday that its Interpace Diagnostics subsidiary will enter the molecular diagnostics market through the acquisition of two microRNA-based from Asuragen.

NEW YORK (GenomeWeb) – Molecular diagnostics developer DiamiR said today it has received a grant from the Michael J. Fox Foundation for Parkinson's Research for a study to validate the use of microRNA biomarkers for detecting Parkinson's early.

NEW YORK (GenomeWeb) – Trovagene has assigned all of its miRNA patents to London-based firm GenSignia IP and licensed back the technology, the San Diego-based company disclosed in its Form 10-Q filed with the US Securities and Exchange Commission recently.

NEW YORK (GenomeWeb News) – Exiqon today reported a 5 percent increase year over year in its revenues for 2013, while revenues in its fourth quarter shrank 16 percent.

NEW YORK (GenomeWeb News) –Rosetta Genomics today announced it has executed credentialing agreements with two preferred provider organizations for its Cancer Origin Test.

NEW YORK (GenomeWeb News) – Blood expression levels of a dozen microRNAs may help in distinguishing individuals affected by Alzheimer's disease from those who aren't, according to a study appearing online today in Genome Biology.

NEW YORK (GenomeWeb News) – Rosetta Genomics said after the close of the market on Thursday it and Precision Therapeutics have amended their co-marketing deal entered into in July 201

NEW YORK (GenomeWeb News) – Partners in Denmark have joined to embark on a €5.2 million ($6.8 million) personalized cancer diagnostic project.

After buying small microRNA firm Prestizia last June, France's Theradiag is moving forward in development of several miRNA tests in the HIV disease area, as well as two companion diagnostic projects for experimental therapies, one for HIV and another for obesity under a $1.6 mill

Pages

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.